134 related articles for article (PubMed ID: 12853364)
1. Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true?
Balzarotti M; Magagnoli M; Santoro A
Ann Oncol; 2003 Jul; 14(7):1155-6. PubMed ID: 12853364
[No Abstract] [Full Text] [Related]
2. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
3. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
4. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
[TBL] [Abstract][Full Text] [Related]
5. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
Kostakoglu L
Clin Lymphoma Myeloma; 2008 Oct; 8(5):273-6. PubMed ID: 18854280
[No Abstract] [Full Text] [Related]
6. Staging and monitoring response to treatment in primary non-Hodgkin's lymphoma of bone marrow using (18)F-fluorodeoxyglucose positron emission tomography.
Matthies A; Schuster SJ; Alavi A
Clin Lymphoma; 2001 Mar; 1(4):303-6; discussion 307. PubMed ID: 11707846
[TBL] [Abstract][Full Text] [Related]
7. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
[No Abstract] [Full Text] [Related]
8. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
[TBL] [Abstract][Full Text] [Related]
10. Late clinically silent perforation of intestinal non-Hodgkin's lymphoma.
Kotb R; Turcotte E; McFadden N; Gomes M; Sawan B; Schmutz G
Clin Lymphoma Myeloma; 2006 May; 6(6):484-7. PubMed ID: 16796780
[TBL] [Abstract][Full Text] [Related]
11. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography in the management of patients with indolent non-Hodgkin's lymphoma.
Naumann R; Beuthien-Baumann B
Clin Lymphoma; 2003 Jun; 4(1):50-1. PubMed ID: 12837155
[No Abstract] [Full Text] [Related]
13. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
Lowe VJ; Wiseman GA
J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627
[No Abstract] [Full Text] [Related]
14. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
15. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract.
Tempescul A; Querellou S; Ianotto JC; Boisramé S; Valette G; Berthou C
Ann Hematol; 2010 Jun; 89(6):635-7. PubMed ID: 19844711
[No Abstract] [Full Text] [Related]
17. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
Jerusalem GH; Beguin YP
Clin Lymphoma; 2002 Jun; 3(1):56-61. PubMed ID: 12141957
[TBL] [Abstract][Full Text] [Related]
18. A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response.
Komoto D; Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Toyama Y; Satoh K; Ohno M; Kanenishi K; Ohkawa M
Ann Nucl Med; 2006 Feb; 20(2):157-60. PubMed ID: 16615426
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of 18F-FDG positron emission tomography in the early evaluation of the efficiency of treatment in patients with non-Hodgkin lymphomas].
Khodzhibekova MM; Tiutin LA; Kostenikov NA; Il'in NV; Vinogradova IuN
Vestn Rentgenol Radiol; 2014; (4):38-41. PubMed ID: 25775886
[TBL] [Abstract][Full Text] [Related]
20. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
